Functional representation of olfactory impairment in early alzheimer's disease

Journal of Alzheimer's Disease

Volumn 22, Issue 2, 2010, Pages 581-591

  Förster, Stefan ^a   Vaitl, Andreas ^a   Teipel, Stefan J ^b,c   Yakushev, Igor ^d   Mustafa, Mona ^a   La Fougère, Christian ^a   Rominger, Axel ^a   Cumming, Paul ^a   Bartenstein, Peter ^a   Hampel, Harald ^b,e   Hummel, Thomas ^f   Buerger, Katharina ^b   Hundt, Walter ^g   Steinbach, Silke ^f,g  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^g PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Alzheimer's disease; FDG PET; mild cognitive impairment; olfactory system; smell test

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FUSIFORM GYRUS; HUMAN; INFERIOR FRONTAL GYRUS; MALE; OLFACTORY DISCRIMINATION; OLFACTORY SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMELLING; SMELLING DISORDER; SNIFFING; SUPERIOR PARIETAL LOBULE;

EID: 78650828988     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-091549     Document Type: Article

References (60)

1. Ward CD, Hess WA, Calne DB (1983) Olfactory impairment in Parkinson's disease. Neurology 33, 943-946.
2. Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5, 235-245.
3. Doty RL, Riklan M, Deems DA, Reynolds C, Stellar S (1989) The olfactory and cognitive deficits of Parkinson's disease: evidence for independence. Ann Neurol 25, 166-171.
4. Devanand DP, Michaels-Marston KS, Liu X, Pelton GH, Padil-la M, Marder K, Bell K, Stern Y, Mayeux R (2000) Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. Am J Psychiatry 157, 1399-1405.
5. Djordjevic J, Jones-Gotman M, De Sousa K, Chertkow H (2008) Olfaction in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 29, 693-706.
6. Devanand DP, Liu X, Tabert MH, Pradhaban G, Cuasay K, Bell K, de Leon MJ, Doty RL, Stern Y, Pelton GH (2008) Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry 64, 871-879.
7. Mesholam RI, Moberg PJ, Mahr RN, Doty RL (1998) Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases. Arch Neurol 55, 84-90.
8. Warner MD, Peabody CA, Flattery JJ, Tinklenberg JR (1986) Olfactory deficits and Alzheimer's disease. Biol Psychiatry 21, 116-118.
9. Doty RL, Reyes PF, Gregor T (1987) Presence of both odor identification and detection deficits in Alzheimer's disease. Brain Res Bull 18, 597-600.
10. Kesslak JP, Cotman CW, Chui HC, Van den Noort S, Fang H, Pfeffer R, Lynch G (1988) Olfactory tests as possible probes for detecting and monitoring Alzheimer's disease. Neurobiol Aging 9, 399-403.
11. Murphy C (1999) Loss of olfactory function in dementing disease. Physiol Behav 66, 177-182.
12. Serby M, Larson P, Kalkstein D (1991) The nature and course of olfactory deficits in Alzheimer's disease. Am J Psychiatry 148, 357-360.
13. Braak H, Braak E (1997) Diagnostic criteria for neuropatho-logic assessment of Alzheimer's disease. Neurobiol Aging 18, S85-S88.
14. Gottfried JA (2006) Smell: central nervous processing. Adv Otorhinolaryngol 63, 44-69.
15. Zatorre RJ, Jones-Gotman M, Evans AC, Meyer E (1992) Functional localization and lateralization of human olfactory cortex. Nature 360, 339-340.
16. Savic I, Gulyas B, Larsson M, Roland P (2000) Olfactory functions are mediated by parallel and hierarchical processing. Neuron 26, 735-745.
17. Buchsbaum MS, Kesslak JP, Lynch G, Chui H, Wu J, Sicotte N, Hazlett E, Teng E, Cotman CW (1991) Temporal and hip-pocampal metabolic rate during an olfactory memory task assessed by positron emission tomography in patients with dementia of the Alzheimer type and controls. Preliminary studies. Arch Gen Psychiatry 48, 840-847.
18. Teipel SJ, Willoch F, Ishii K, Burger K, Drzezga A, Engel R, Bartenstein P, Moller HJ, Schwaiger M, Hampel H (2006) Resting state glucose utilization and the CERAD cognitive battery in patients with Alzheimer's disease. Neurobiol Aging 27, 681-690.
19. Desgranges B, Baron JC, de la Sayette V, Petit-Taboue MC, Benali K, Landeau B, Lechevalier B, Eustache F (1998) The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization. Brain 121(Pt 4), 611-631.
20. Desgranges B, Baron JC, Lalevee C, Giffard B, Viader F, de La Sayette V, Eustache F (2002) The neural substrates of episodic memory impairment in Alzheimer's disease as revealed by FDG-PET: relationship to degree of deterioration. Brain 125, 1116-1124.
21. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME (2001) Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. Jama 286, 2120-2127.
22. Chetelat G, Desgranges B, de la Sayette V, Viader F, Berkouk K, Landeau B, Lalevee C, Le Doze F, Dupuy B, Hannequin D, Baron JC, Eustache F (2003) Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. Brain 126, 1955-1967.
23. Herholz K (2003) PET studies in dementia. AnnNuclMed 17, 79-89.
24. Friedland RP, Brun A, Budinger TF (1985) Pathological and positron emission tomographic correlations in Alzheimer's disease. Lancet 1, 228.
25. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. ArchNeurol 58, 19851992.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
27. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746.
28. Jagust W, Reed B, Mungas D, Ellis W, Decarli C (2007) What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 69, 871-877.
29. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE, A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. JNucl Med 36, 1238-1248.
30. Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJ, Verm-ersch P, Steinling M, Valk J (1993) A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 114, 7-12.
31. Kobal G, Hummel T, Sekinger B, Barz S, Roscher S, Wolf S (1996) "Sniffin' sticks": screening of olfactory performance. Rhinology 34, 222-226.
32. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G (1997) "Sniffin' sticks": olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses 22, 39-52.
33. Hummel T, Kobal G, Gudziol H, Mackay-Sim A (2007) Normative data for the "Sniffin' Sticks" including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol 264, 237-243.
34. Friston KJ, Frith CD, Liddle PF, Frackowiak RS (1991) Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab 11, 690-699.
35. Forster S, Teipel S, Zach C, Rominger A, Cumming P, Fougere CL, Yakushev I, Haslbeck M, Hampel H, Bartenstein P, Burger K (2010) FDG-PET mapping the brain substrates of visuo-constructive processing in Alzheimer s disease. J Psychiatr Res 44, 462-469.
36. Yakushev I, Hammers A, Fellgiebel A, Schmidtmann I, Scheurich A, Buchholz HG, Peters J, Bartenstein P, Lieb K, Schreckenberger M (2009) SPM-based count normalization provides excellent discrimination ofmild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging. Neuroimage 44, 43-50.
37. Borghammer P, Jonsdottir KY, Cumming P, Ostergaard K, Vang K, Ashkanian M, Vafaee M, Iversen P, Gjedde A (2008) Normalization in PET group comparison studies -the importance of a valid reference region. Neuroimage 40, 529-540.
38. Borghammer P, Cumming P, Aanerud J, Forster S, Gjedde A (2009) Subcortical elevation of metabolism in Parkinson's disease -A critical reappraisal in the context of global mean normalization. Neuroimage 47, 1514-1521.
39. Borghammer P, Cumming P, Aanerud J, Gjedde A (2009) Arte-factual subcortical hyperperfusion in PET studies normalized to global mean: lessons from Parkinson's disease. Neuroimage 45, 249-257.
40. Fusari A, Ballesteros S (2008) Identification of odors of edible and nonedible stimuli as affected by age and gender. Behav Res Methods 40, 752-759.
41. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, Hotton G, Cutler D, Fox N, Kennedy A, Rossor M, Brooks DJ (2007) Amyloid, hypometabolism, and cognition in Alzheimer disease: an 11C.PIB and 18F .FDG PET study.Neurology 68, 501-508.
42. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM (2002) Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 159, 738-745.
43. Lancaster JL, Woldorff MG, Parsons LM, Liotti M, Freitas CS, Rainey L, Kochunov PV, Nickerson D, Mikiten SA, Fox PT (2000) Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp 10, 120-131.
44. Dubois B, Picard G, Sarazin M (2009) Early detection of Alzheimer's disease: new diagnostic criteria. Dialogues Clin Neurosci 11, 135-139.
45. Yuan Y, Gu ZX, Wei WS (2009) Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNRAmJNeuroradiol 30, 404-410.
46. Atighechi S, Salari H, Baradarantar MH, Jafari R, Karimi G, Mirjali M (2009) A comparative study of brain perfusion single-photon emission computed tomography and magnetic resonance imaging in patients with post-traumatic anosmia. Am JRhinol Allergy 23, 409-412.
47. Hedner M, Larsson M, Arnold N, Zucco GM, Hummel T Cognitive factors in odor detection, odor discrimination, and odor identification tasks. J Clin Exp Neuropsychol, 1-6.
48. Savic I, Berglund H (2004) Passive perception of odors and semantic circuits. Hum Brain Mapp 21, 271-278.
49. Kronenbuerger M, Zobel S, Ilgner J, Finkelmeyer A, Reinacher P, Coenen VA, Wilms H, Kloss M, Kiening K, Daniels C, Falk D, Schulz JB, Deuschl G, Hummel T Effects of deep brain stimulation of the cerebellothalamic pathways on the sense of smell. Exp Neurol 222, 144-152.
50. Tham WW, Stevenson RJ, Miller LA (2009) The functional role of the medio dorsal thalamic nucleus in olfaction. Brain Res Rev 62, 109-126.
51. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
52. Geddes JW, Tekirian TL, Soultanian NS, Ashford JW, Davis DG, Markesbery WR (1997) Comparison of neuropathologic criteria for the diagnosis of Alzheimer's disease. Neurobiol Aging 18, S99-105.
53. Kumar A, Schapiro MB, Grady C, Haxby JV, Wagner E, Salerno JA, Friedland RP, Rapoport SI (1991) High-resolution PET studies in Alzheimer's disease. Neuropsychopharmacology 4, 35-46.
54. Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32, 486-510.
55. Mosconi L, Tsui WH, De Santi S, Li J, Rusinek H, Convit A, Li Y, Boppana M, de Leon MJ (2005) Reduced hippocam-pal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 64, 1860-1867.
56. Ashford JW, Shan M, Butler S, Rajasekar A, Schmitt FA (1995) Temporal quantification of Alzheimer's disease severity: "time index" model. Dementia 6, 269-280.
57. Ashford JW, Shih WJ, Coupal J, Shetty R, Schneider A, Cool C, Aleem A, Kiefer VH, Mendiondo MS, Schmitt FA (2000) Single SPECT measures of cerebral cortical perfusion reflect time-index estimation of dementia severity in Alzheimer's disease. J Nucl Med 41, 57-64.
58. Ashford JW, JarvikL (1985) Alzheimer's disease: does neuron plasticity predispose to axonal neurofibrillary degeneration? N Engl J Med 313, 388-389.
59. Velayudhan L, Lovestone S (2009) Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezil. J Clin Psychopharmacol 29, 387-390.
60. Haehner A, Mayer AM, Landis BN, Pournaras I, Lill K, Gudziol V, Hummel T (2009) High test-retest reliability of the extended version of the " Sniffin' Sticks" test. Chem Senses 34, 705-711.